Zanoterone

Zanoterone (INN, USAN) (former developmental codename WIN-49596) is a steroidal antiandrogen. It was investigated for the treatment of benign prostatic hyperplasia (BPH) but failed to demonstrate sufficient efficacy in phase II clinical trials, and also showed an unacceptable incidence rate and severity of side effects (e.g., gynecomastia). As such, it was not further developed, and hence was never marketed.